Isthmin inhibits glioma growth through antiangiogenesis in vivo

J Neurooncol. 2012 Sep;109(2):245-52. doi: 10.1007/s11060-012-0910-8. Epub 2012 Jul 7.

Abstract

Among glioma treatment strategies, antiangiogenesis emerges as a meaningful and feasible treatment approach for inducing long-term survival. Isthmin is a gene highly expressed in the isthmus of the midbrain-hindbrain organizer in Xenopus, and has recently been identified as a novel angiogenesis inhibitor. However, the potential of isthmin on the glioma angiogenesis has not been well studied. In the present study, we demonstrated that the recombinant adenovirus isthmin (Ad-isthmin) could inhibit VEGF-stimulated endothelial cell proliferation and induce apoptosis through a caspase-dependent pathway. In addition, Ad-isthmin significantly suppressed glioma growth through antiangiogenesis without apparent side effects. Taken together, our results demonstrated that isthmin could act as a novel angiogenesis inhibitor and might be utilized in the glioma antiangiogenesis therapy.

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Animals
  • Apoptosis / drug effects
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / mortality
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Female
  • Flow Cytometry
  • Glioma / drug therapy*
  • Glioma / mortality
  • Humans
  • Intercellular Signaling Peptides and Proteins
  • Mice
  • Mice, Nude
  • Microvessels / pathology
  • Proteins / therapeutic use*
  • Statistics, Nonparametric
  • Survival Analysis
  • Transduction, Genetic
  • Xenograft Model Antitumor Assays

Substances

  • Angiogenesis Inhibitors
  • Intercellular Signaling Peptides and Proteins
  • Proteins
  • isthmin protein, mouse